Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:CRNX NASDAQ:INSM NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$92.45+1.5%$91.42$79.52▼$124.00$23.04B1.32719,851 shs679,282 shsCRNXCrinetics Pharmaceuticals$83.86+0.0%$51.34$25.83▼$84.00$8.84B0.238.62 million shs2.32 million shsINSMInsmed$104.13-0.6%$105.09$90.39▼$212.75$22.70B0.782.24 million shs1.95 million shsROIVRoivant Sciences$33.84-2.5%$32.47$10.90▼$37.00$24.97B1.114.47 million shs4.40 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+1.49%+0.13%+1.35%-8.98%-18.03%CRNXCrinetics Pharmaceuticals+0.01%-0.05%+128.50%+118.16%+176.77%INSMInsmed-0.57%-4.13%+0.73%-22.88%+2.34%ROIVRoivant Sciences-2.53%-3.20%-0.68%+22.97%+198.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$92.45+1.5%$91.42$79.52▼$124.00$23.04B1.32719,851 shs679,282 shsCRNXCrinetics Pharmaceuticals$83.86+0.0%$51.34$25.83▼$84.00$8.84B0.238.62 million shs2.32 million shsINSMInsmed$104.13-0.6%$105.09$90.39▼$212.75$22.70B0.782.24 million shs1.95 million shsROIVRoivant Sciences$33.84-2.5%$32.47$10.90▼$37.00$24.97B1.114.47 million shs4.40 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+1.49%+0.13%+1.35%-8.98%-18.03%CRNXCrinetics Pharmaceuticals+0.01%-0.05%+128.50%+118.16%+176.77%INSMInsmed-0.57%-4.13%+0.73%-22.88%+2.34%ROIVRoivant Sciences-2.53%-3.20%-0.68%+22.97%+198.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.74Moderate Buy$129.1339.67% UpsideCRNXCrinetics Pharmaceuticals 2.24Hold$81.00-3.41% DownsideINSMInsmed 3.00Buy$209.35101.04% UpsideROIVRoivant Sciences 2.75Moderate Buy$33.59-0.74% DownsideCurrent Analyst Ratings BreakdownLatest CRNX, ROIV, INSM, and BNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2026INSMInsmed Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$235.007/28/2026CRNXCrinetics Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$55.00 ➝ $85.007/20/2026INSMInsmed BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$192.007/20/2026INSMInsmed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$220.007/20/2026INSMInsmed BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2026CRNXCrinetics Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026INSMInsmed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026INSMInsmed Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$160.00 ➝ $161.007/10/2026INSMInsmed GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$207.007/8/2026BNTXBioNTech Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$126.00 ➝ $119.007/8/2026CRNXCrinetics Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$3.25B7.20$1.35 per share68.23$96.59 per share0.96CRNXCrinetics Pharmaceuticals$7.70M1,148.34N/AN/A$9.71 per share8.64INSMInsmed$606.42M37.22N/AN/A$3.46 per share30.10ROIVRoivant Sciences$8.26M2,946.74N/AN/A$7.35 per share4.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/4/2026 (Estimated)CRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/4/2026 (Estimated)INSMInsmed-$1.28B-$5.75N/A176.49N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)ROIVRoivant Sciences-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/6/2026 (Estimated)Latest CRNX, ROIV, INSM, and BNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026INSMInsmed-$0.69N/AN/AN/A$393.40 millionN/A8/6/2026Q1 2027ROIVRoivant Sciences-$0.33N/AN/AN/A$2.00 millionN/A8/4/2026Q2 2026BNTXBioNTech-$2.3999N/AN/AN/A$183.75 millionN/A8/4/2026Q2 2026CRNXCrinetics Pharmaceuticals-$1.23N/AN/AN/A$14.84 millionN/A5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74CRNXCrinetics PharmaceuticalsN/A18.6018.56INSMInsmed0.804.474.10ROIVRoivant SciencesN/A18.3718.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%CRNXCrinetics Pharmaceuticals98.51%INSMInsmedN/AROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%CRNXCrinetics Pharmaceuticals3.80%INSMInsmed2.10%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionableINSMInsmed1,664216.75 million212.20 millionOptionableROIVRoivant Sciences860719.27 million641.59 millionOptionableCRNX, ROIV, INSM, and BNTX HeadlinesRecent News About These CompaniesRoivant Sciences Ltd. $ROIV Holdings Lessened by SB Investment Advisers UK Ltd.2 hours ago | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Moderate Buy" from Analysts4 hours ago | americanbankingnews.comRoivant Sciences Ltd. $ROIV is ADAR1 Capital Management LLC's 3rd Largest PositionJuly 29 at 3:03 AM | marketbeat.comRoivant Sciences Ltd. $ROIV Shares Sold by Rubric Capital Management LPJuly 28 at 6:55 AM | marketbeat.comMaverick Capital Ltd. Takes $45.07 Million Position in Roivant Sciences Ltd. $ROIVJuly 28 at 6:07 AM | marketbeat.comRoivant Sciences (ROIV) Receives a Buy from Piper SandlerJuly 26 at 6:19 AM | theglobeandmail.comDimensional Fund Advisors LP Sells 1,771,602 Shares of Roivant Sciences Ltd. $ROIVJuly 25, 2026 | marketbeat.comBank of Nova Scotia Cuts Stake in Roivant Sciences Ltd. $ROIVJuly 25, 2026 | marketbeat.comAllspring Global Investments Holdings LLC Buys New Stake in Roivant Sciences Ltd. $ROIVJuly 25, 2026 | marketbeat.comRoivant Sciences Ltd. $ROIV Stake Boosted by Affinity Asset Advisors LLCJuly 25, 2026 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 24, 2026 | marketbeat.comCalifornia Public Employees Retirement System Invests $19.15 Million in Roivant Sciences Ltd. $ROIVJuly 24, 2026 | marketbeat.comImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026July 23, 2026 | globenewswire.comBaader Bank Aktiengesellschaft Sells 33,612 Shares of Roivant Sciences Ltd. $ROIVJuly 23, 2026 | marketbeat.comBank of New York Mellon Corp Decreases Stock Holdings in Roivant Sciences Ltd. $ROIVJuly 22, 2026 | marketbeat.comBillionaire Ramaswamy's wealth has surged as he runs for Ohio governorJuly 21, 2026 | usatoday.comJennison Associates LLC Boosts Holdings in Roivant Sciences Ltd. $ROIVJuly 20, 2026 | marketbeat.comIllinois Municipal Retirement Fund Boosts Stake in Roivant Sciences Ltd. $ROIVJuly 20, 2026 | marketbeat.comPrincipal Financial Group Inc. Boosts Holdings in Roivant Sciences Ltd. $ROIVJuly 20, 2026 | marketbeat.comOhio Chamber wrong. Vivek Ramaswamy's love of money won't create jobs here | LettersJuly 18, 2026 | msn.comRoivant Sciences Ltd. $ROIV Stake Raised by Dorsey Wright & AssociatesJuly 18, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 2026CRNX, ROIV, INSM, and BNTX Company DescriptionsBioNTech NASDAQ:BNTX$92.45 +1.36 (+1.49%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$91.95 -0.50 (-0.54%) As of 08:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Crinetics Pharmaceuticals NASDAQ:CRNX$83.86 +0.01 (+0.01%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$83.82 -0.03 (-0.04%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Insmed NASDAQ:INSM$104.13 -0.60 (-0.57%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$104.08 -0.05 (-0.05%) As of 08:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Roivant Sciences NASDAQ:ROIV$33.84 -0.88 (-2.53%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$34.20 +0.36 (+1.06%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
